tirzepatide otro nombre *TIRZEPATIDA* -Es un medicamento inyectable semanal, aprobado para el tratamiento de la diabetes tipo 2 y la obesidad., -Actúa como doble agonista de los receptores GIP y GLP-1, mejorando el control 🧬 QUIMFA presentó oficialmente TIRZEC

In 1997, the Food and Drug Administration (FDA) requested the withdrawal of fenfluramine and dexfenfluramine (another component used in some Fen-Phen combinations) from the market

Learn why GLP-1/GIP activation triggers it, when it resolves, danger signs, and 6 strategies that work.

In the landmark SURMOUNT-1 trial, participants on the 15 mg dose achieved average weight loss of 22.5% of body weight over 72 weeks

However, individual results may vary, and it could take several months before you experience the full benefits of the medication

Patients should always follow the specific instructions provided with their prescribed medication and consult their GP or pharmacist if uncertain